(600332)"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Subsidiary's Drug Passing the Generic Drug Consistency Evaluation
Filed with SSE · Stock code 600332 · · 3 pages · Chinese
Summary by 6ix AI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its subsidiary has successfully passed the consistency evaluation for a generic drug. The drug, Amikacin Sulfate Injection, is now approved for quality and efficacy consistency, enhancing its market competitiveness. The announcement also highlights potential risks related to production and sales influenced by national policies and market conditions.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited on 6ix
Story so far
- Announcement on Receipt of the Drug Clinical Trial Approval Notice by Subsidiary
- (600332)"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Completion of Filing for Change of Manager of the Equity Investment Fund and Progress of Related Party Transactions
- (600332)"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Receipt of Drug Registration Certificate by Subsidiary
Earlier from Guangzhou Baiyunshan Pharmaceutical
- Announcement on Receipt of the Drug Clinical Trial Approval Notice by Subsidiary
- (600332)"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Receipt of Drug Registration Certificate by Subsidiary
- (600332)"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited"Announcement on Completion of Filing for Change of Manager of the Equity Investment Fund and Progress of Related Party Transactions
- Indicative Announcement on Change in Equity Structure of Controlling Shareholder
- Announcement on Changes to Matters Concerning the Equity Investment Fund and Progress of the Related Party Transaction
Follow Guangzhou Baiyunshan Pharmaceutical into a list and get an email when it puts out news.
Follow Guangzhou Baiyunshan Pharmaceutical